Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation of long arms of chromosomes 9 and 22 (Philadelphia chromosome). Since the approval of Imatinib in 2001, Dasatinib and Nilotinib have been approved for use in Imatinib resistant or intolerant as well as front line treatment for CML cases. The most common side effects of these kinase inhibitors include myelosuppression, nausea, vomiting, diarrhea, mild skin rash, and QTc prolongation, but serious allergic reactions are rare. Here, we present a case series of Nilotinib induced dermatologic toxicities.